Oryzon Genomics S.A. (0RDB.L)
| Previous close | 1.8680 |
| Open | 1.8880 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.8880 - 1.8880 |
| 52-week range | 1.6020 - 2.3950 |
| Volume | |
| Avg. volume | 2,518 |
| Market cap | 68.982M |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0880 |
| Earnings date | 16 Oct 2024 - 20 Oct 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia
Exploring the triple combination with venetoclax and azacitidineStudy sponsored by Oregon Health & Science University (OHSU) MADRID and CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in an investigator-initiated Phase Ib dose-finding trial of iadademstat,
- GlobeNewswire
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications
In Australia, Malaysia and Mexico MADRID and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has received additional “Decision to grant” communications for important patents relating vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders
- GlobeNewswire
ORYZON to Provide Corporate Progress Updates at Several Events in September
German Fall Conference 2024European College of Neuropsychopharmacology (ECNP) congress 2024Sachs Annual Biotech in Europe Forum 2024 MADRID, Spain and CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in
